Clinical trial
Intense Monitoring Study on Sintilimab Injection (Tyvyt®)
NCT04237233 is registered in ClinicalTrials.gov with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Intense Monitoring Study on Sintilimab Injection (Tyvyt®)
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- April 2, 2020
- Completion date
- December 31, 2023
- Enrollment
- 300 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory classical hodgkin's lymphoma